Pancreatic Adenocarcinoma Metastatic Clinical Trial
Official title:
The Efficacy and Safety of PD-1 Antibody Combined With Sapropterin Dihydrochloride in Patients With Advanced Pancreatic Cancer Who Failed to Standard Treatment.
The prognosis for pancreatic cancer remains dismal, with current guidelines favoring FOLFIRINOX or AG (consisting of Gemcitabine and Abraxane) as the primary chemotherapeutic option. However, research has indicated limited benefits for patients with pancreatic cancer undergoing immunotherapy using Anti-PD-1 antibodies. In this context, researchers aim to investigate the therapeutic potential of Sapropterin Dihydrochloride combined with PD-1 antibody in patients with metastatic pancreatic cancer who failed to standard treatment.
There is no standard treatment for patients with metastatic pancreatic cancer who failed to FOLFIRINOX or AG (consisting of Gemcitabine and Abraxane). Patients with metastatic pancreatic cancer who are unable to tolerate or have failed to respond to standard chemotherapy will be enrolled in this clinical trial. They will be administered a combination treatment of Sapropterin Dihydrochloride and PD-1 antibody. The primary endpoints of this study are objective response rate and safety. The secondary endpoints will encompass overall survival, progression-free survival, and quality of life. The study aims to enroll a total of 20 participants. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06006728 -
Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy
|
||
| Terminated |
NCT03213626 -
Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05077800 -
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT01715142 -
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer
|
Early Phase 1 | |
| Completed |
NCT02179970 -
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
|
Phase 1 | |
| Completed |
NCT02195180 -
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06051851 -
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT03633734 -
Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03529175 -
Scheduling Nab-paclitaxel With Gemcitabine
|
Phase 2 | |
| Recruiting |
NCT05360264 -
tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr
|
Phase 2 | |
| Recruiting |
NCT04150042 -
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
|
Phase 1 | |
| Withdrawn |
NCT03127124 -
QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06076837 -
The Seven Trial: Exploiting the Unfolded Protein Response
|
Phase 1 | |
| Completed |
NCT01053013 -
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
|
Phase 2 |